Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)
Clinicaltrials.gov identifier:
NCT02997228
This is a treatment study is for people with metastatic colorectal cancer
Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study
About the Study
This study is no longer recruiting people.
This study is for people with colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient () or have an MSI-H diagnosis, which are commonly seen in people with .
This study is no longer recruiting people.
This study is no longer recruiting people.